Heilbronn, Germany
June 22, 2007
greenovation Biotech GmbH
announces the granting of their first US patent in the area of
plant-based glyco-engineering. This patent offers wide-ranging
protection for the targeted processing of a plant-specific sugar
residue.
First patent from a complete patent family
Scientists at greenovation
Biotech GmbH have been able to build on many years of
experience in the area of the design of production strains in
moss, in their work on targeted improvements in
biopharmaceuticals through glyco-engineering. Through specific
genetic modifications of the expression system, such as
knockouts and the over-expression of glycosyltransferases, the
sugar structures of the produced proteins could be adapted to
those of human beings.
The proprietary foundation for this work is based, amongst other
things, on patent applications that have been licensed globally
and exclusively by greenovation. After widely granting
throughout Europe, now the first patent from the patent family
has also been granted in the USA. This patent offers a broad
protection for the targeted processing of a plant-specific sugar
residue. After the granting of the patent, greenovation’s CSO,
Dr. Gilbert Gorr commented, “The US pharmaceuticals market is by
far the market with the strongest turnover and for this reason,
the granting of this patent, is very significant for mapping out
the future direction for our company.”
The granting of this patent, will enable greenovation Biotech
GmbH to build on its position as the world’s leading company in
the manufacturing of therapeutic glycoproteins in plants.
The greenovation Biotech GmbH company is specialized in the
design and the production of complex pharmaceutical proteins.
Mosses, cultivated in so-called photo-bioreactors, serve as a
platform for the sustainable, safe and economic production of
therapeutically more effective biopharmaceuticals. |
|
